What Is Patient Experience Data? The Regulatory Perspective

Published May 21, 2018
Defining Patient Experience Data in Light of the US 21st Century Cures Act Baltimore, MD, USA—May 21, 2018—ISPOR, the professional society for health economics and outcomes research, held a session, “What Is Patient Experience Data? The Regulatory Perspective [W2],” this morning at ISPOR 2018 in Baltimore, MD, USA. This session was led by speakers from a variety of divisions at the US Food and Drug Administration (FDA) in Sliver Spring, MD, USA:
  • Martin Ho, MS, Center for Devices and Radiological Health (CDRH)
  • Megan Moncur, MS, Center for Biologics Evaluation and Research (CBER)
  • Pujita Vaidya, MPH, Office of Strategic Programs/Office of Program and Strategic Analysis, Center for Drug Evaluation and Research (CDER)
Over the past 5 years, the US FDA has made strides toward incorporating the “patient voice” in medical product decision-making. The Patient-Focused Drug Development and Patient Preference initiatives, begun under the FDA Safety and Innovation Act (FDASIA) of 2012, led to 24 public meetings held to learn from patients about their disease experience and to produce a guidance document about patient preference information in medical device applications. The 21st Century Cures Act and other FDA initiatives have helped to solidify the objectives of these initiatives. The speakers discussed current efforts to promote and advance the incorporation of patient input into the regulatory decision making processes. Providing examples of patient experience data and its application in medical product development, they identified opportunities for patient stakeholders to help strengthen capacity and advance fit-for-purpose methods and tools. Additional information on ISPOR 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBaltimore.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

ISPOR Announces Launch of ISPOR Institute for Healthcare Transformation

Nov 10, 2025

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced the launch of its new ISPOR Institute for Healthcare Transformation. The ISPOR Institute is an organic extension of ISPOR that bridges the gap between research and real-world application to further elevate the relevance, use, and impact of HEOR.

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×